IL323718A - טיפול משולב הכולל מעכב parg ומעכב טופואיזומראז לטיפול בסרטן - Google Patents

טיפול משולב הכולל מעכב parg ומעכב טופואיזומראז לטיפול בסרטן

Info

Publication number
IL323718A
IL323718A IL323718A IL32371825A IL323718A IL 323718 A IL323718 A IL 323718A IL 323718 A IL323718 A IL 323718A IL 32371825 A IL32371825 A IL 32371825A IL 323718 A IL323718 A IL 323718A
Authority
IL
Israel
Prior art keywords
compound
cancer
inhibitor
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
IL323718A
Other languages
English (en)
Original Assignee
Ideaya Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ideaya Biosciences Inc filed Critical Ideaya Biosciences Inc
Publication of IL323718A publication Critical patent/IL323718A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL323718A 2023-04-05 2025-09-30 טיפול משולב הכולל מעכב parg ומעכב טופואיזומראז לטיפול בסרטן IL323718A (he)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363457312P 2023-04-05 2023-04-05
US202363584013P 2023-09-20 2023-09-20
US202363548513P 2023-11-14 2023-11-14
PCT/US2024/022979 WO2024211506A1 (en) 2023-04-05 2024-04-04 Combination therapy comprising a parg inhibitor and a topoisomerase inhibitor for treating cancer

Publications (1)

Publication Number Publication Date
IL323718A true IL323718A (he) 2025-11-01

Family

ID=91022661

Family Applications (1)

Application Number Title Priority Date Filing Date
IL323718A IL323718A (he) 2023-04-05 2025-09-30 טיפול משולב הכולל מעכב parg ומעכב טופואיזומראז לטיפול בסרטן

Country Status (7)

Country Link
EP (1) EP4687894A1 (he)
CN (1) CN121335701A (he)
AU (1) AU2024253809A1 (he)
IL (1) IL323718A (he)
MX (1) MX2025011869A (he)
TW (1) TW202446376A (he)
WO (1) WO2024211506A1 (he)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025064750A1 (en) * 2023-09-20 2025-03-27 Ideaya Biosciences, Inc. Combination therapy with a parg inhibitor
TW202528308A (zh) * 2023-09-20 2025-07-16 美商愛德亞生物科學公司 Parg抑制劑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI873187B (zh) 2019-09-20 2025-02-21 美商愛德亞生物科學公司 作為parg抑制劑之4-取代的吲哚及吲唑磺醯胺衍生物
US20230272485A1 (en) * 2022-02-16 2023-08-31 Boundless Bio, Inc. Replication stress pathway agent compositions and methods for treating cancer
AU2023239344A1 (en) * 2022-03-23 2024-10-10 Ideaya Biosciences, Inc. Piperazine substituted indazole compounds as inhibitors of parg

Also Published As

Publication number Publication date
TW202446376A (zh) 2024-12-01
AU2024253809A1 (en) 2025-10-16
EP4687894A1 (en) 2026-02-11
WO2024211506A1 (en) 2024-10-10
MX2025011869A (es) 2025-12-01
CN121335701A (zh) 2026-01-13

Similar Documents

Publication Publication Date Title
IL323718A (he) טיפול משולב הכולל מעכב parg ומעכב טופואיזומראז לטיפול בסרטן
US10647700B2 (en) EZH2 inhibitor and use thereof
IL263245A (he) שיטה לטיפול בלייפת כבד
IL295662A (he) תרכובות מקרוציקליות ושימושים בהן
IL307392A (he) טיפולים מעורבים עם מונעי prmt5 לטיפול בסרטן
IL259354A (he) מעכבים של cxcr2
US20250222116A1 (en) Parp-1 degradation agent and use thereof
IL284326B2 (he) מעכבי mat2a אזא-הטרוביציקליים ושיטות לשימוש לטיפול בסרטן
US20240343736A1 (en) Kras inhibitors
IL296835A (he) תהליך להכנת מעכב parp, צורות גבישיות ושימושיהן
IL266126A (he) תרכובת פירידון כמעכב c–met
IL278281B2 (he) צורה גבישית של מעכב c–met וצורת המלח שלו ושיטה להכנתן
IL229505A (he) תכשירים המכילים ,שיטות המערבות ושימושים של חומצות אמינו לא טבעיות הקשורות לתולדות דולאסטטין
IL298306A (he) מפעילי ampk
TW201136934A (en) Deuterated pyrrolopyrimidine compounds as inhibitors of CDK4/6
IL307393A (he) טיפולים מעורבים המשמשים במונעי prmt5 לטיפול בסרטן
IL303962A (he) תרכובת הטריציקלית
IL267299B (he) מעכב cdk4/6
Jiang et al. Discovery of novel phenoxyaryl pyridones as bromodomain and extra-terminal domain (BET) inhibitors with high selectivity for the second bromodomain (BD2) to potentially treat acute myeloid leukemia
CN112745298A (zh) 多取代异吲哚啉类化合物、其制备方法、药物组合物及用途
JP2024500562A (ja) Ａｌｃ１阻害剤およびｐａｒｐｉとの相乗効果
NO342001B1 (no) C-kit kinase inhibitor for anvendelse i terapeutisk behandling av gastrointestinal stromaltumor eller mastocytose.
AU2023265886A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
IL323379A (he) אצילסולפונאמיד מעכבי kat6a
Lin et al. Design, synthesis, biological evaluation of novel piperidine-based derivatives as potent poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors